BMS 986171

Drug Profile

BMS 986171

Alternative Names: BMS986171

Latest Information Update: 23 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Healthy subjects presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 05 Nov 2016 Bristol-Myers Squibb completes a phase-I clinical trial in Hepatic fibrosis and Non-alcoholic steatohepatitis (In volunteers) in USA (SC) (NCT02538874)
  • 31 Oct 2015 Phase-I clinical trials in Hepatic fibrosis (In volunteers) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top